| 摘要 |
The present invention relates to new piperidyl- or piperazinyl-substituted dihydro-2H-1-benzopyran derivatives having the formula (I) wherein X is N; Y is NR<SUB>2</SUB>CH<SUB>2</SUB>, CH<SUB>2</SUB>NR<SUB>2</SUB>, NR<SUB>2</SUB>CO, CONR<SUB>2</SUB>, NR<SUB>2</SUB>SO<SUB>2 </SUB>or NR<SUB>2</SUB>CONR<SUB>2 </SUB> wherein R<SUB>2 </SUB>is H or C<SUB>1</SUB>-C<SUB>6 </SUB>alkyl; R<SUB>1 </SUB>is H, C<SUB>1</SUB>-C<SUB>6 </SUB>alkyl or C<SUB>3</SUB>-C<SUB>6 </SUB>cycloalkyl; R<SUB>3 </SUB>is C<SUB>1</SUB>-C<SUB>6 </SUB>alkyl, C<SUB>3</SUB>-C<SUB>6 </SUB>cycoalkyl or (CH<SUB>2</SUB>)<SUB>n</SUB>-aryl, wherein aryl is a heteromatic ring containing one or two heteroatoms selected from N, O and S and which may be mono- or di-substituted with R<SUB>4 </SUB>and/or R<SUB>5</SUB>; and n is 0-4; as (R)-enantiomers, (S)-enantiomers or racemates in the form of a free base or a pharmaceutically acceptable salt or solvate thereof, a process for their preparation, pharmaceutical compositions containing said therapeutically active compounds and to the use of said active compounds.
|
